Therefore, risk reductions by dapagliflozin, an SGLT2 inhibitor, in the progression of CKD and HF among most of the subjects without T2DM are also independent of hyperfiltration and tubuloglomerular feedback. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.